BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Table 2 Best tumor responses as per Response Evaluation Criteria in Solid Tumors version 1.1 between the regorafenib combined with programmed cell death-1 inhibitor and regorafenib monotherapy groups, n (%)
Best Response
Overall response
Intrahepatic response
Extrahepatic response
RP group (n = 101)
R group (n = 39)
P value
RP group (n = 101)
R group (n = 39)
P value
RP group (n = 52)
R group (n = 22)
P value
CR0 (0.00)0 (0.00)1.0000 (0.00)0 (0.00)1.0000 (0.00)0 (0.00)1.000
PR4 (3.96)0 (0.00)0.5764 (3.96)0 (0.00)0.5753 (5.77)0 (0.00)0.550
SD66 (65.35)15 (38.46)0.00580 (79.21)23 (58.97)0.03128 (53.85)7 (31.82)0.126
PD31 (30.69)24 (61.54)0.00117 (16.83)15 (38.46)0.00721 (40.38)15 (68.18)0.042
ORR4 (3.96)0 (0.00)0.5764 (3.96)0 (0.00)0.5753 (5.77)0 (0.00)0.550
DCR70 (69.31)15 (38.46)0.00184 (83.17)23 (58.97)0.00731 (59.62)7 (31.82)0.0042


Write to the Help Desk